Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Sarah Alspach

    Chief Communications Officer

    (857) 299-6198

    sarah.alspach@bluebirdbio.com

  • Jess Rowlands

    Senior Director, Product Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team

  • Read more about bluebird bio Secures Additional $30 Million in Financing; ARCH Venture Partners Joins Investor Team

bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.

  • Read more about bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.

bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology

  • Read more about bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology

bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference

  • Read more about bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference

bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference

  • Read more about bluebird bio to Present at the Rodman & Renshaw Annual Global Investment Conference

bluebird bio Secures $60 Million in Oversubscribed Financing

  • Read more about bluebird bio Secures $60 Million in Oversubscribed Financing

BIO Welcomes bluebird bio CEO Nick Leschly to the Health Section Governing Board

  • Read more about BIO Welcomes bluebird bio CEO Nick Leschly to the Health Section Governing Board

bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy

  • Read more about bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy

John Maraganore, Ph.D., Joins the bluebird bio Board of Directors

  • Read more about John Maraganore, Ph.D., Joins the bluebird bio Board of Directors

bluebird bio to Present at the Cowen and Company 32nd Annual Healthcare Conference

  • Read more about bluebird bio to Present at the Cowen and Company 32nd Annual Healthcare Conference

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Current page 41
  • Page 42
  • Page 43
  • Next page Next ›
  • Last page Last »
Subscribe to

Quick Links

  • Patients & Advocacy
  • Investors & Media
  • Careers
  • Contact Us

CONTACT INFO

info@bluebirdbio.com

clinicaltrials@bluebirdbio.com

investor@bluebirdbio.com

medinfo@bluebirdbio.com

Live - Terms & Privacy

  • Terms of Service
  • Privacy Policy
  • Cookie Notice
  • Sitemap
© 2022 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

Live - Social Links